Kyverna Completes Miv-cel BLA Submission
Kyverna submitted its BLA for miv-cel in stiff person syndrome under RMAT, seeking a potential 2027 launch. The event holds broad relevance as the first CAR-T therapy submission in an autoimmune disease and advances the company's commercial readiness.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed